Quantcast

Industry news that matters to you.  Learn more

ImaginAb Enters into Exclusive Licensing Agreement with UCLA for Immune Cell Imaging Agents

ImaginAb, Inc. and the Regents of the University of California, Los Angeles (UCLA) have executed a technology licensing agreement relating to novel immune cell-targeting agents for imaging with Positron Emission Tomography (PET). Inflammation and immune response play a fundamental role in a wide variety of diseases including cancer and autoimmune diseases. Under the agreement, ImaginAb gains exclusive access to novel imaging agents that target specific markers of murine T-cells, enabling a new understanding of response to immunotherapeutic drugs in pre-clinical models.

ImaginAb and Duke-NUS Launch Imaging Biomarker Development Lab (IBDL)

ImaginAb, Inc. recently announced that it has entered into a partnership with the Duke-NUS Graduate Medical School Singapore (Duke-NUS) to establish a joint corporate laboratory to develop new in vivo molecular imaging agents to study cancer biology and immune function. ImaginAb is a U.S. clinical-stage company that develops in vivo molecular imaging agents based on a proprietary antibody fragment technology platform. ImaginAb’s mission is to transform the clinical management of cancer and autoimmune diseases via targeted molecular imaging.